News & Events

Bacteria as a vehicle for drug delivery

WIPO | MAGAZINE August 2014

ActoGeniX, a small Belgian biotech company, is breaking new ground in developing a new class …


Jefferies 2014 Global Healthcare Conference

November 19-20, 2014
Waldorf Hilton, London



RESI Conference

September 17, 2014
Fenway Park, Boston, MA



BIO-Europe 2014 – Presentation

November 3-5, 2014
Portalhaus Messe Frankfurt, Germany



Flemish Biotech and Life Sciences week (Japan)

October 14 – 20, 2014


Bio Investor Forum

BIO Investor Forum – Presentation

October 7-8, 2014
The Palace Hotel, San Francisco



14th Annual Biotech in Europe Forum for Global Partnering & Investment – Presentation

30 September – 1 October 2014
Congress Center Basel, Switzerland



STALLERGENES and ActoGeniX to develop together an innovative new class of oral treatments for allergy

STALLERGENES to develop and commercialize novel oral allergy drugs based on ActoGeniX’s proprietary local mucosal delivery technology
ActoGeniX eligible for…


ActoGeniX closes EUR 10.7 million financing round

Ghent, Belgium – April 18th, 2013

ActoGeniX, a clinical stage biopharmaceutical company, successfully closed a Series B equity financing round, …


Knowledge for Growth – Presentation

May 30, 2013
ICC Ghent